Project Grant HT94252510574

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $417,984 to the Scripps Research Institute to support a research project focused on the study of FOXP3 and regulatory T cell fate. The key objectives of the project are to: Identify the biomolecular target and mechanism of action for the small molecule A205804 in inducing functional CD4+ regulatory T cell differentiation...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to investigate the role of the PPARD/CIITA/MHCII axis in regulating regulatory T cell (Treg) function and its impact on tumor immunity. The $276,450 award to the Salk Institute for Biological Studies will fund experiments to define the molecular mechanisms by which MHCII expression in Tregs is regulated by...

This $650,450 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of Southern California (USC) aims to advance the development of T cell receptor (TCR)-engineered CD4+ T cell immunotherapy for lung cancer. The key objectives of the award are to: 1) determine the mechanisms by which the novel MIIC4 TCRM50A-STEM2 T cell product eliminates lung cancer cells; 2) produce GMP-grade master cell bank and viral particles, and...

The National Institutes of Health (NIH), through the Cancer Biology Research program (CFDA 93.396), awarded a $618,928 Project Grant to The Regents of the University of California, doing business as the University of California, Berkeley (UC Berkeley). The award, effective June 9, 2025, with a final completion date of May 31, 2030, will support research to investigate the mechanisms by which regulatory T cells (Tregs) suppress antitumor immune responses within the tumor microenvironment and...

This $300,000 federal Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to engineer human regulatory T cells (Tregs) with a chimeric antigen receptor (CAR) targeting NTPDase3 on B cells for controlling type 1 diabetes (T1D). The project, led by Sanford Research, will test CAR Tregs with varying antigen binding affinities to optimize their activation, proliferation, and suppressive function against islet-reactive T...

This Project Grant award of $775,992.00 from the National Heart, Lung, and Blood Institute (NHLBI)'s Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of regulatory T cells (Tregs) and glucocorticoid signaling in the resolution of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The key objectives are to determine the function of Treg glucocorticoid receptor (GR) signaling and the impact of exogenous glucocorticoid...

This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $703,000.00 to the Research Institute at Nationwide Children's Hospital (RINCH) for the "Preclinical Development of Micro-Tuberin Gene Therapy for Tuberous Sclerosis Complex Type 2". The award period runs from April 1, 2025 to March 31, 2027. The primary objectives of this research project are to develop and qualify a targeted proteomics...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $709,019 to the Benaroya Research Institute at Virginia Mason to study the role of the FOXP3 isoform in regulating autoantibody production and the development of systemic lupus erythematosus (SLE). The key objectives are to: Determine the role of FOXP3E2-expressing regulatory T cells in germinal center function and the...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $739,236 to support research on the cellular mechanisms underlying resistance to mTOR inhibitors in lymphangioleiomyomatosis (LAM), a rare and destructive lung disease. The research aims to elucidate the role of the YAP-WNT signaling pathway in driving sirolimus (an mTOR inhibitor) insensitivity, which can lead to disease...

This $693,880 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of a novel cancer immunotherapy approach using engineered CD4+ T cells. The goal is to create CD4+ T cells that can target the tumor microenvironment and overcome resistance to current immune checkpoint inhibitor therapies. Key elements include: Identifying key molecules and immune cell targets of the engineered CD4+ T cells in preclinical cancer...